Tirzepatide may be ideal for adults with a BMI over 27, those struggling with insulin resistance, or individuals who have not achieved lasting results through diet and exercise alone
CNBC also reports that a study found that, now that Wegovy is approved to treat heart disease in obese patients, more than 3 million Americans on Medicare could be eligible for prescription coverage of these drugs, noting that the programs budget could be strained as Wegovy is now covered by their Part D prescription plan
"We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them." "For many of them, that wait is over as we can now offer the powerful efficacy of Wegovy in a once-daily pill that demonstrated about 17% weight loss, if all patients stayed on treatment," said Ed Cinca, Senior Vice President, Marketing & Patient Solutions at Novo Nordisk
patients with certain variants in the FTO and MC4R genes sometimes experience longer adjustment periods, and knowing this can help set realistic expectations
Semaglutide In monotherapy trials with semaglutide injection for type 2 diabetes mellitus (T2DM), severe hypoglycemia (requiring the assistance of another person) was not reported in either the treatment group or the placebo group
